Anthacyclines in non-small cell lung cancer

被引：0
|
作者：
Pronzato, P [1 ]
Vigani, A
Tognoni, A
Vaira, F
Canessa, P
机构：
[1] Osped S Angrea, Dept Med Oncol, I-19100 La Spezia, Italy
[2] Osped S Andrea, Dept Pneumol, I-19100 La Spezia, Italy
来源：
LUNG CANCER | 2001年 / 34卷
关键词：
non-small cell lung cancer; chemotherapy; anthracyclines;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The literature concerning the use of anthracyclines in the treatment of non-small cell lung cancer (NSCLC) is reviewed here. Overall. the activity of doxorubicin (DOXO) is unsatisfactory, whereas, the analogous epidoxorubicin (EPI) yields a 30% response rate (RR) when administered at intermediate-high doses. All active drugs, including EPI. should be considered to design the most active combination. Mainly. in the setting. in which an objective response is very important. for instance the neo-adjuvant pre-operatory setting. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码：S57 / S59
页数：3
相关论文
共 50 条
  • [1] Non-small cell lung cancer
    Hill, Andrew
    Fisher, Patricia
    Yeomanson, Dan
    BRITISH MEDICAL JOURNAL, 2012, 345
  • [2] Non-small cell lung cancer
    Besse, B.
    Vignot, S.
    ONCOLOGIE, 2013, 15 (7-8) : 371 - 376
  • [3] Non-small cell lung cancer
    Nestle, U.
    Hoffmann, H.
    Reck, M.
    Bruns, C.
    ONKOLOGIE, 2022, 28 (12): : 1034 - 1037
  • [4] Non-small cell lung cancer
    Sause, W
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 39 (02): : 126 - 126
  • [5] Non-Small Cell Lung Cancer
    Ettinger, David S.
    Akerley, Wallace
    Borghaei, Hossein
    Chang, Andrew C.
    Cheney, Richard T.
    Chirieac, Lucian R.
    D'Amico, Thomas A.
    Demmy, Todd L.
    Ganti, Apar Kishor P.
    Govindan, Ramaswamy
    Grannis, Frederic W., Jr.
    Horn, Leora
    Jahan, Thierry M.
    Jahanzeb, Mohammad
    Kessinger, Anne
    Komaki, Ritsuko
    Kong, Feng-Ming
    Kris, Mark G.
    Krug, Lee M.
    Lennes, Inga T.
    Loo, Billy W., Jr.
    Martins, Renato
    O'Malley, Janis
    Osarogiagbon, Raymond U.
    Otterson, Gregory A.
    Patel, Jyoti D.
    Pinder-Schenck, Mary C.
    Pisters, Katherine M.
    Reckamp, Karen
    Riely, Gregory J.
    Rohren, Eric
    Swanson, Scott J.
    Wood, Douglas E.
    Yang, Stephen C.
    Hughes, Miranda
    Gregory, Kristina M.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (10): : 1236 - 1271
  • [6] Non-small cell lung cancer
    M. Dediu
    W. Hilbe
    memo - Magazine of European Medical Oncology, 2008, 1 (4) : 247 - 251
  • [7] Non-small cell lung cancer
    Adamietz, I. A.
    Niederle, N.
    ONKOLOGE, 2010, 16 (06): : 63 - 74
  • [8] ;Non-small cell lung cancer
    Dediu, M.
    Hilbe, W.
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2008, 1 (04) : 247 - 251
  • [9] Small RNAs and non-small cell lung cancer
    Tong, Alex W.
    CURRENT MOLECULAR MEDICINE, 2006, 6 (03) : 339 - 349
  • [10] NON-SMALL CELL LUNG-CANCER
    HASKELL, CM
    HOLMES, EC
    CURRENT PROBLEMS IN CANCER, 1987, 11 (01) : 1 - 53
12345